Form 4: Exelixis EVP and CFO Christopher J. Senner Executes Option and Sells Shares
SEC Form 4
Christopher J. Senner, EVP and CFO of Exelixis, exercised options to acquire 125,000 shares of common stock and simultaneously sold the same amount on August 9, 2024.
Summary
- On August 9, 2024, Christopher J. Senner, the EVP and CFO of Exelixis, exercised an option to purchase 125,000 shares of Exelixis common stock at a price of $24.41 per share.
- Simultaneously, Senner sold 125,000 shares of Exelixis common stock at a weighted average price of $27.19, with individual sales prices ranging from $27.08 to $27.35.
- Following these transactions, Senner directly owns 721,680 shares of Exelixis common stock and indirectly owns 2,723 shares through the Exelixis, Inc. 401(k) Plan.
- Senner also holds 272,874 shares of Exelixis, Inc. common stock that will be issued to him upon vesting of restricted stock units.
Sentiment
Score: 5
Explanation: This Form 4 filing is a routine disclosure of an executive's stock transactions. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.
Industry Context
Executive stock transactions are common and closely watched as they can provide insights into management's perspective on the company's value and future prospects. However, single transactions are not always indicative of the overall health of the company.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- The exercise of options and subsequent sale of shares is a typical way for executives to realize the value of their equity compensation.
- Similar transactions are regularly reported by executives at comparable biotech companies such as Gilead Sciences, Amgen, and Biogen.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership, but it's unlikely to be significant given the relatively small number of shares involved compared to the total outstanding shares.
- The transaction has no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 10/03/2018 | Date the option became exercisable |
| 10/02/2024 | Expiration date of the option |
| 08/08/2024 | Date of plan statement for Exelixis, Inc. 401(k) Plan |
| 08/09/2024 | Date of transaction: Exercise of option and sale of shares |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.